Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications

Neurology

Volumn 86, Issue 3, 2016, Pages 231-240

  Löhle, Matthias ^a,c,d   Mende, Julia ^a   Wolz, Martin ^a   Beuthien Baumann, Bettina ^a,b   Oehme, Liane ^a   Van Den Hoff, Jörg ^b   Kotzerke, Jörg ^a   Reichmann, Heinz ^a   Storch, Alexander ^a,c,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; FLUORINE 18; LEVODOPA; DOPA; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE DURATION; EFFECTIVE DISTRIBUTION VOLUME RATIO; FEMALE; FOLLOW UP; HUMAN; LEVODOPA-INDUCED DYSKINESIA; MALE; MEDICAL RECORD; MOTOR DYSFUNCTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR PUTAMEN; PREDICTIVE VALUE; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL; UNIFIED PARKINSON DISEASE RATING SCALE; VOLUME OF DISTRIBUTION RATIO; WEARING OFF; AGED; COMPLICATION; DYSKINESIAS; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; SCINTISCANNING; SINGLE BLIND PROCEDURE;

AGED; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE AGENTS; DYSKINESIAS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PUTAMEN; SINGLE-BLIND METHOD;

EID: 84955252135     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002286     Document Type: Article

References (40)

1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311:1670-1683.
2. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193.
3. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
4. Hechtner MC, Vogt T, Zollner Y, et al. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 2014;20:969-974.
5. Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 2011;69:919-927.
6. Hong JY, Oh JS, Lee I, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology 2014;82:1597-1604.
7. de la Fuente-Fernandez R, Pal PK, Vingerhoets FJ, et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 2000;107:49-57.
8. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-860.
9. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009;72:1211-1216.
10. Linazasoro G, Antonini A, Maguire RP, Leenders KL. Pharmacological and PET studies in patients with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. J Neural Transm 2004;111:497-509.
11. Storch A, Wolz M, Beuthien-Baumann B, et al. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology 2013;80:1754-1761.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neuro-surg Psychiatry 1992;55:181-184.
13. Fahn S, Elton RL, Committee UD. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent Developments in Parkinson's Disease. Florham Park: Macmillan Healthcare Information; 1987:153-163, 293-304.
14. Stacy M, Hauser R, Oertel W, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006;29:312-321.
15. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25: 2649-2653.
16. Sossi V, de La Fuente-Fernandez R, Holden JE, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 2002; 22:232-239.
17. Doudet DJ, Chan GL, Holden JE, et al. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998;29:225-232.
18. Oehme L, Perick M, Beuthien-Baumann B, et al. Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with (1) (8)F-dopa brain PET in normal controls and patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2011;38:1550-1559.
19. Sossi V, Doudet DJ, Holden JE. A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 2001;21:469-476.
20. Sossi V, Holden JE, de la Fuente-Fernandez R, Ruth TJ, Stoessl AJ. Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki. J Cereb Blood Flow Metab 2003;23:301-309.
21. Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-1071.
22. Wills AM, Eberly S, Tennis M, et al. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord 2013;28:380-383.
23. de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004; 127:888-899.
24. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
25. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levo-dopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
26. Sossi V, de la Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004;24:869-876.
27. Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009; 72:S32-S38.
28. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopa-minergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296.
29. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984;41:856-861.
30. Sossi V, de la Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006;129:1050-1058.
31. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007; 62:468-474.
32. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996;119:2097-2103.
33. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009; 132:2970-2979.
34. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
35. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain: II: patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122:1437-1448.
36. Morissette M, Samadi P, Hadj Tahar A, Belanger N, Di Paolo T. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:446-454.
37. Heiman M, Heilbut A, Francardo V, et al. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci USA 2014;111:4578-4583.
38. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dys-kinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694-2706.
39. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopa-mine processing in Parkinson's disease. Brain 2011;134: 3290-3298.
40. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.